P

Inventor

WINTER GEORG

AT18 patents
⚠️ This page may combine multiple inventors who share the name “WINTER GEORG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

DANA FARBER CANCER INST INC

17 patents
US10125114B2Nov 13, 2018

Methods to induce targeted protein degradation through bifunctional molecules

DANA FARBER CANCER INST INC57 citations97
US9821068B2Nov 21, 2017

Methods to induce targeted protein degradation through bifunctional molecules

DANA FARBER CANCER INST INC71 citations97
US9770512B2Sep 26, 2017

Methods to induce targeted protein degradation through bifunctional molecules

DANA FARBER CANCER INST INC63 citations97
US9750816B2Sep 5, 2017

Methods to induce targeted protein degradation through bifunctional molecules

DANA FARBER CANCER INST INC62 citations97
US9694084B2Jul 4, 2017

Methods to induce targeted protein degradation through bifunctional molecules

DANA FARBER CANCER INST INC76 citations97
US10849980B2Dec 1, 2020

Methods to induce targeted protein degradation through bifunctional molecules

DANA FARBER CANCER INST INC16 citations94
US10669253B2Jun 2, 2020

Methods to induce targeted protein degradation through bifunctional molecules

DANA FARBER CANCER INST INC17 citations94
US10464925B2Nov 5, 2019

Methods to induce targeted protein degradation through bifunctional molecules

DANA FARBER CANCER INST INC36 citations94
US11583586B2Feb 21, 2023

Methods to induce targeted protein degradation through bifunctional molecules

DANA FARBER CANCER INST INC3 citations73
US11059801B2Jul 13, 2021

Methods to induce targeted protein degradation through bifunctional molecules

DANA FARBER CANCER INST INC2 citations73
US11311609B2Apr 26, 2022

Regulating chimeric antigen receptors

DANA FARBER CANCER INST INC6 citations71
US11046954B2Jun 29, 2021

Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses

DANA FARBER CANCER INST INC2 citations71
US10899768B2Jan 26, 2021

Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use

DANA FARBER CANCER INST INC3 citations71
US11293023B2Apr 5, 2022

Tunable endogenous protein degradation

DANA FARBER CANCER INST INC0 citations61
US10925868B2Feb 23, 2021

Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use

DANA FARBER CANCER INST INC0 citations61
US11578075B2Feb 14, 2023

Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use

DANA FARBER CANCER INST INC1 citations60
US12023385B2Jul 2, 2024

Tunable endogenous protein degradation with heterobifunctional compounds

DANA FARBER CANCER INST INC0 citations49

PROXYGEN GMBH

1 patent